GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Cash Flow from Financing

Curative Biotechnology (Curative Biotechnology) Cash Flow from Financing : $0.32 Mil (TTM As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2023, Curative Biotechnology paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.02 Mil from issuing more debt. It received $0.16 Mil more from issuing preferred shares than it paid to buy back preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Curative Biotechnology earned $0.18 Mil on financial activities for the three months ended in Mar. 2023.


Curative Biotechnology Cash Flow from Financing Historical Data

The historical data trend for Curative Biotechnology's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology Cash Flow from Financing Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
Get a 7-Day Free Trial - - 0.39 2.07 1.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.13 0.09 -0.08 0.18

Curative Biotechnology Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Curative Biotechnology's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Curative Biotechnology's Cash from Financing for the quarter that ended in Mar. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curative Biotechnology  (OTCPK:CUBT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Curative Biotechnology's issuance of stock for the three months ended in Mar. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Curative Biotechnology's repurchase of stock for the three months ended in Mar. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Curative Biotechnology's net issuance of debt for the three months ended in Mar. 2023 was $0.02 Mil. Curative Biotechnology received $0.02 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Curative Biotechnology's net issuance of preferred for the three months ended in Mar. 2023 was $0.16 Mil. Curative Biotechnology received $0.16 Mil more from issuing preferred shares than it paid to buy back preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Curative Biotechnology's cash flow for dividends for the three months ended in Mar. 2023 was $0.00 Mil. Curative Biotechnology received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Curative Biotechnology's other financing for the three months ended in Mar. 2023 was $0.00 Mil. Curative Biotechnology received $0.00 Mil on other financial activities.


Curative Biotechnology Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Curative Biotechnology (Curative Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.

Curative Biotechnology (Curative Biotechnology) Headlines

From GuruFocus

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

By GuruFocusNews GuruFocusNews 06-21-2022

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

By GuruFocusNews GuruFocusNews 05-12-2022

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

By GuruFocusNews GuruFocusNews 05-22-2022